**Positive Phase 3 results for Moderna and Merck’s personalized mRNA neoantigen therapy intismeran autogene (mRNA-4157/V940) in August 2026 are the main driver of current trader sentiment.** The INTerpath-001 trial in resected high-risk melanoma met its primary recurrence-free survival endpoint and key secondary distant metastasis-free survival endpoint versus pembrolizumab alone, marking the first such success for an individualized mRNA cancer vaccine. Five-year Phase 2 follow-up data reinforced durable benefit with roughly a 49% reduction in recurrence or death risk. Companies are engaging regulators on filing and plan to present full data at an upcoming medical meeting. While no Biologics License Application has been submitted yet, the readout supports accelerated timelines toward potential approval. Other skin cancer immunotherapies, including Replimune’s recently approved oncolytic virus for PD-1-refractory cases, highlight a competitive adjuvant landscape but operate in different mechanistic niches. Key near-term catalysts include detailed trial results and FDA feedback on submission readiness.